Off-brand GLP-1s still widely available despite shortage resolutions

SAN DIEGO — Non-FDA-approved GLP-1 receptor agonists remain largely available despite recent resolutions to drug shortages, data at the Obesity Medicine Association’s annual meeting indicate.
Michael J. DiStefano, PhD, MBE, an assistant professor of pharmaceutical outcomes research at the University of Colorado Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences, explained during a presentation that compounding is “a process where pharmacists or physicians mix or alter the ingredients of a drug to produce a medication that meets the specific need of an individual patient.”
According




